Evidence map›Paper›PMID 25327812›Full record

Trial reportActa pharmacologica Sinica2014

Effects of an Al(3+)- and Mg(2+)-containing antacid, ferrous sulfate, and calcium carbonate on the absorption of nemonoxacin (TG-873870) in healthy Chinese volunteers.

Yi-fan Zhang, Xiao-jian Dai, Ting Wang, Xiao-yan Chen, Li Liang, Hua Qiao, Cheng-yuan Tsai, Li-wen Chang, Ping-ting Huang, Chiung-yuan Hsu and 3 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Acta pharmacologica Sinica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Yi-fan ZhangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Xiao-jian DaiShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Ting WangThe First Hospital Affiliated to Lanzhou University, Lanzhou 730000, China.
Xiao-yan ChenShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Li LiangThe First Hospital Affiliated to Lanzhou University, Lanzhou 730000, China.
Hua QiaoThe First Hospital Affiliated to Lanzhou University, Lanzhou 730000, China.
Cheng-yuan TsaiTaiGen Biotechnology Co Ltd, Taipei 11470, Taiwan, China.
Li-wen ChangTaiGen Biotechnology Co Ltd, Taipei 11470, Taiwan, China.
Ping-ting HuangTaiGen Biotechnology Co Ltd, Taipei 11470, Taiwan, China.
Chiung-yuan HsuTaiGen Biotechnology Co Ltd, Taipei 11470, Taiwan, China.
Yu-ting ChangTaiGen Biotechnology Co Ltd, Taipei 11470, Taiwan, China.
Chen-en TsaiTaiGen Biotechnology Co Ltd, Taipei 11470, Taiwan, China.
Da-fang ZhongShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Beike Biotechnology (China) · CNChinese Academy of Sciences · CNTaiGen Biotechnology (Taiwan) · TWLanzhou University · CNShanghai Institute of Materia Medica · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo evaluate the effects of an Al(3+)- and Mg(2+)-containing antacid, ferrous sulfate, and calcium carbonate on the absorption of nemonoxacin in healthy humans.

methodsTwo single-dose, open-label, randomized, crossover studies were conducted in 24 healthy male Chinese volunteers (12 per study). In Study 1, the subjects orally received nemonoxacin (500 mg) alone, or an antacid (containing 318 mg of Al(3+) and 496 mg of Mg(2+)) plus nemonoxacin administered 2 h before, concomitantly or 4 h after the antacid. In Study 2, the subjects orally received nemonoxacin (500 mg) alone, or nemonoxacin concomitantly with ferrous sulfate (containing 60 mg of Fe(2+)) or calcium carbonate (containing 600 mg of Ca(2+)).

resultsConcomitant administration of nemonoxacin with the antacid significantly decreased the area under the concentration-time curve from time 0 to infinity (AUC0-∞) for nemonoxacin by 80.5%, the maximum concentration (Cmax) by 77.8%, and urine recovery (Ae) by 76.3%. Administration of nemonoxacin 4 h after the antacid decreased the AUC0-∞ for nemonoxacin by 58.0%, Cmax by 52.7%, and Ae by 57.7%. Administration of nemonoxacin 2 h before the antacid did not affect the absorption of nemonoxacin. Administration of nemonoxacin concomitantly with ferrous sulfate markedly decreased AUC0-∞ by 63.7%, Cmax by 57.0%, and Ae by 59.7%, while concomitant administration of nemonoxacin with calcium carbonate mildly decreased AUC0-∞ by 17.8%, Cmax by 14.3%, and Ae by 18.4%.

conclusionMetal ions, Al(3+), Mg(2+), and Fe(2+) markedly decreased the absorption of nemonoxacin in healthy Chinese males, whereas Ca(2+) had much weaker effects. To avoid the effects of Al(3+) and Mg(2+)-containing drugs, nemonoxacin should be administered ≥2 h before them.

Indexed as

Administration, OralAdultAluminum HydroxideAntacidsAnti-Infective AgentsArea Under CurveAsian PeopleCalcium CarbonateChinaCross-Over StudiesDrug Administration ScheduleDrug InteractionsFerrous CompoundsGastrointestinal AbsorptionHalf-LifeHealthy VolunteersAluminum HydroxideAntacidsAnti-Infective AgentsCalcium CarbonateFerrous Compoundsferrous sulfateMagnesium HydroxidenemonoxacinQuinolones

Identifiers

PMID25327812
PMCPMC4261130
OpenAlexW2048184546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.